RxDoctor Payments Data

Brittney Burdick, PA

Physician Assistant · Jacksonville, FLNPI 1780824136

Payments from drug & device makers

$9,002in general payments, 2019–2025

Across 495 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AstraZeneca$752
  • Novo Nordisk$743
  • Abbott$735
  • AbbVie$653
  • Lilly USA, LLC$546
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$8,90499%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,002 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$40,448
Medicare patients
90
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide112$123,480
OzempicSemaglutide62$73,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$53,658
EliquisApixaban30$43,110
VraylarCariprazine Hcl23$35,723
JardianceEmpagliflozin24$31,282
WegovySemaglutide17$25,079
UbrelvyUbrogepant14$21,895
XareltoRivaroxaban23$18,729
JanuviaSitagliptin Phosphate12$18,060
FarxigaDapagliflozin Propanediol17$16,804
Nurtec OdtRimegepant Sulfate12$13,954
LinzessLinaclotide13$13,211
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,907
SymbicortBudesonide/Formoterol Fumarate22$6,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$546$123,480112 claims
Novo NordiskOzempic, Wegovy$743$98,90979 claims
AbbVieVraylar, Ubrelvy, Linzess$653$70,82950 claims
PfizerEliquis, Nurtec Odt$101$57,06542 claims
GSKTrelegy Ellipta$489$53,65865 claims
Boehringer IngelheimJardiance, Stiolto Respimat$290$40,18839 claims
AstraZenecaFarxiga, Symbicort$752$23,26039 claims
Johnson & JohnsonXarelto$115$18,72923 claims
MerckJanuvia$166$18,06012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →